Tratamiento médico del aborto espontáneo del primer trimestre

Purpose To evaluate the cost‐effectiveness of a strategy based on direct‐acting uterine curettage (UC) versus a pre‐direct‐acting misoprostol (1600 mg) in patients with missed abortion (MA), from the perspective of a National Health System. Methods An open prospective cohort study was carried out at Reina Sofía University Hospital (Córdoba, Spain) from January 1, 2019 to December 31, 2019 in 180 patients diagnosed with MA. The patients chose medical treatment with intravaginal misoprostol (800 μg/4 h) or UC after receiving complete and detailed information. The effectiveness, clinical characteristics of the patients, costs of treating and managing the disease, and satisfaction with the procedures were recorded. Results One hundred and forty‐five patients (80.6%) chose misoprostol versus 35 patients (19.4%) who chose UC. The effectiveness of misoprostol has been 42% evaluated at 48 h; UC success rate has been 100%. The incidence of side effects is significantly higher in patients treated with misoprostol (p < 0.05); as well as the number of care received by the patient (p < 0.05). Satisfaction is higher in patients treated with UC (p < 0.05). However, the cost is almost 5‐folds higher in patients treated with UC (p < 0.05). Conclusion UC has a higher success rate, greater satisfaction, and a lower incidence of side effects, although significantly increases the cost compared to misoprostol in MA.

show abstract

Intravaginal misoprostol versus uterine curettage for missed abortion: A cost‐effectiveness analysis

Torres-Miranda

Gómez

Lobo-Gonçalves

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tratamiento médico del aborto espontáneo del primer trimestre

Cited by 1 publication

References 150 publications

Intravaginal misoprostol versus uterine curettage for missed abortion: A cost‐effectiveness analysis

Intravaginal misoprostol versus uterine curettage for missed abortion: A cost‐effectiveness analysis

Contact Info

Product

Resources

About